EF Hutton analyst Tony Butler assumed coverage of CEL-SCI with a Buy rating and $10 price target. CEL-SCI is developing an immunotherapy known as Multikine to fight against cancer and a "pre-BLA" meeting with the FDA has not yet been scheduled, the firm noted.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CVM:
